U.S. Scrutiny of Chinese Company Could Disrupt U.S. Supply Chain for Key Drugs
Posted inBiotechnology and Bioengineering Cancer China Cystic Fibrosis Delaware Drugs (Pharmaceuticals) Eli Lilly and Company Factories and Manufacturing GlaxoSmithKline PLC Government Contracts and Procurement House of Representatives Intellectual Property Janssen Pharmaceutica Labor and Jobs Leukemia Massachusetts People's Liberation Army (China) Research Senate Shortages Start-ups Supply Chain Tax Credits, Deductions and Exemptions United States International Relations United States Politics and Government

U.S. Scrutiny of Chinese Company Could Disrupt U.S. Supply Chain for Key Drugs

Lawmakers raising national security concerns and seeking to disconnect a major Chinese firm from U.S. pharmaceutical interests have rattled the biotech industry. The firm is deeply involved in development and manufacturing of crucial therapies for cancer, cystic fibrosis, H.I.V. and other illnesses.
The Medicine Is a Miracle, but Only if You Can Afford It
Posted inCancer Drugs (Pharmaceuticals) Eczema Genetic Engineering Grants (Corporate and Foundation) Health Insurance and Managed Care Immunotherapy Income Inequality Inflation Reduction Act of 2022 Leukemia Medicare Multiple Sclerosis Philanthropy Research United States

The Medicine Is a Miracle, but Only if You Can Afford It

A wave of new treatments have cured devastating diseases. When the costs are too much, even for the insured, patients hunt for other ways to pay.